tiprankstipranks
Advertisement
Advertisement
Veracyte price target raised to $42 from $40 at Canaccord
PremiumThe FlyVeracyte price target raised to $42 from $40 at Canaccord
1M ago
Veracyte price target raised to $52 from $48 at UBS
Premium
The Fly
Veracyte price target raised to $52 from $48 at UBS
1M ago
Veracyte Earns Buy Rating on Consistent Outperformance, Raised Guidance and Attractive Optionality From Upcoming Pipeline Launches
Premium
Ratings
Veracyte Earns Buy Rating on Consistent Outperformance, Raised Guidance and Attractive Optionality From Upcoming Pipeline Launches
1M ago
Veracyte initiated with a Buy at Jefferies
PremiumThe FlyVeracyte initiated with a Buy at Jefferies
2M ago
Veracyte: Leveraging TrueMRD and Decipher Bladder to Capture a $200M Minimal Residual Disease Opportunity
Premium
Ratings
Veracyte: Leveraging TrueMRD and Decipher Bladder to Capture a $200M Minimal Residual Disease Opportunity
2M ago
Veracyte price target lowered to $45 from $50 at Guggenheim
Premium
The Fly
Veracyte price target lowered to $45 from $50 at Guggenheim
2M ago
Veracyte: Accelerating Growth, Expanding Margins, and Pipeline-Driven Upside Support a Raised $48 Price Target
PremiumRatingsVeracyte: Accelerating Growth, Expanding Margins, and Pipeline-Driven Upside Support a Raised $48 Price Target
3M ago
Veracyte reports Q4 EPS 51c, consensus 41c
Premium
The Fly
Veracyte reports Q4 EPS 51c, consensus 41c
3M ago
Veracyte sees FY26 revenue $570M-$582M, consensus $570.3M
Premium
The Fly
Veracyte sees FY26 revenue $570M-$582M, consensus $570.3M
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100